Pure Bioscience (PURE) AI Stock Analysis

• Market Cap: $9.17M
• Dividend Yield: N/A
• Average Volume (3M): 53.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: 31.00%
• EPS Growth: 34.24%
• Country: US
• Employees: 11
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 111,886,475
• 10 Day Avg. Volume: 24,352
• 30 Day Avg. Volume: 53,720
• PEG Ratio: 0.15
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00456
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 1.62
• Enterprise Value/Revenue: 6.19
• Enterprise Value/Gross Profit: 0.01
• Enterprise Value/Ebitda: -8.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.08 ▲(56.00% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is primarily constrained by weak financial performance (negative equity, ongoing losses, and recurring cash burn). Technicals are supportive with strong trend/momentum, but overbought indicators add near-term risk. Valuation is impaired by unprofitability, and the authorized-share increase adds financing flexibility while raising dilution concerns.

Positive Factors

Revenue Growth

Sustained ~31% reported revenue growth indicates the company can expand product adoption and market reach for its SDC disinfectant offerings. If the company can stabilize sales cadence, persistent top-line growth supports scaling fixed-cost absorption and improves the path toward durable profitability.

Strong Historical Gross Margins

Annual gross margins near the mid-50s percent point to attractive unit economics for the core antimicrobial chemistry. Strong product-level margins create structural leverage: with higher and steadier revenues, the company can fund operating expenses and improve operating leverage towards sustainable profitability.

Financing Flexibility via Share Authorization

Expanded authorized shares give management durable flexibility to raise equity, grant compensation, or pursue strategic transactions. That structural option reduces immediate solvency pressure by enabling capital raises to support operations or strategic investments when cash generation remains weak.

Negative Factors

Negative Shareholder Equity

Sustained negative equity signals a materially weakened capital structure and limits financial flexibility. Over months this raises refinancing risk, can restrict access to credit or favorable vendor terms, and makes the business more reliant on dilutive equity or costly debt to fund operations.

Persistent Cash Burn

Consistent negative operating and free cash flow means the company cannot self-fund growth or cover operating needs over the medium term. Continued cash burn increases dependence on external financing, raising dilution or insolvency risk and constraining capacity to invest in commercial expansion.

Revenue Volatility & Unprofitability

Extreme revenue swings and persistent losses hamper forecasting, margin consistency, and strategic planning. Volatility undermines the ability to demonstrate repeatable demand, making it harder to convert margin advantages into sustained net profitability and increasing execution risk over the next several quarters.

Pure Bioscience Business Overview & Revenue Model

Company Description

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

How the Company Makes Money

Pure Bioscience makes money primarily by selling its antimicrobial/disinfecting products and related solutions to customers that need sanitation and hygiene products. Revenue is generated from product sales (e.g., SDC-based disinfectants/sanitizers) distributed through direct sales and/or channel partners, depending on the market and product. Additional monetization can come from licensing or commercialization arrangements tied to its antimicrobial chemistry and trademarks, but specific, current details on material partnerships, pricing structure, customer concentration, or the relative contribution of each revenue stream are null.

Pure Bioscience Financial Statement Overview

Summary

Overall financials are weak: persistent operating losses and negative operating/free cash flow, plus a balance sheet with negative shareholder equity and elevated leverage/refinancing risk. TTM losses and cash burn appear to be narrowing, but extreme revenue volatility and abnormal latest-period margin signals reduce confidence in stability.

Income Statement

Revenue is highly volatile (FY2025 shows an extreme spike vs prior years, then TTM (Trailing-Twelve-Months) drops to a much smaller base), which raises questions about sustainability and comparability. Profitability remains weak: operating profit and net income are negative across all periods provided, although losses have narrowed in TTM (Trailing-Twelve-Months) versus FY2024–FY2023. Gross margin appears strong in the annual periods (~52–59%), but the TTM (Trailing-Twelve-Months) gross margin is abnormally high relative to revenue, suggesting the latest data may include one-time items or classification effects.

Balance Sheet

The balance sheet is pressured by negative shareholder equity in FY2024, FY2025, and TTM (Trailing-Twelve-Months), which materially weakens financial flexibility and increases refinancing risk. Debt levels are elevated relative to the asset base in FY2025 (debt far exceeds total assets) and remain sizable in TTM (Trailing-Twelve-Months). While FY2022 showed a healthier equity position and no debt, the subsequent shift to negative equity signals a significant deterioration in capitalization.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are below zero in every period, indicating the business is not self-funding. There is some improvement in TTM (Trailing-Twelve-Months) versus FY2025 and FY2023–FY2024 (cash burn is smaller), but free cash flow growth is very volatile, including a sharp deterioration in FY2025. Overall, ongoing cash burn combined with a weakened capital structure increases reliance on external funding.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	2.41M	2.20B	1.96M	1.88M	1.85M	3.93M
Gross Profit	1.30B	1.30B	1.15M	971.00K	1.00M	2.08M
EBITDA	-1.80M	-2.10M	-3.05M	-3.83M	-3.27M	-2.14M
Net Income	-2.16M	-2.40M	-3.35M	-3.96M	-3.50M	-2.32M
Balance Sheet
Total Assets	788.00K	1.06B	818.00K	1.82M	4.48M	4.30M
Cash, Cash Equivalents and Short-Term Investments	198.00K	334.00M	349.00K	1.09M	3.39M	2.39M
Total Debt	6.14M	5.24B	2.95M	1.02M	0.00	239.00K
Total Liabilities	7.06M	6.17B	3.68M	1.55M	575.00K	970.00K
Stockholders Equity	-6.27M	-5.12B	-2.86M	272.00K	3.91M	3.33M
Cash Flow
Free Cash Flow	-1.82M	-2.02B	-2.53M	-3.31M	-2.50M	-1.69M
Operating Cash Flow	-1.82M	-2.02B	-2.53M	-3.28M	-2.42M	-1.17M
Investing Cash Flow	0.00	0.00	0.00	-33.00K	-81.00K	-521.00K
Financing Cash Flow	1.82M	2.00B	1.78M	1.01M	3.50M	239.00K

Pure Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 77.27 is Negative, neither overbought nor oversold. The STOCH value of 91.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PURE.

Pure Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UG	74 Outperform	$28.76M	33.63	17.51%	9.81%	-18.29%	-43.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TANH	56 Neutral	$5.13M	2.65	3.65%	―	-14.59%	-135.25%
GROV	48 Neutral	$58.83M	-3.67	-130.15%	―	-15.42%	7.12%
TKLF	47 Neutral	$10.07M	―	16.79%	―	7.75%	-21.61%
MTEX	46 Neutral	$12.83M	2.46	-19.54%	―	-9.17%	-4.64%
PURE	45 Neutral	$9.17M	-1.66	127.81%	―	31.00%	34.24%

Pure Bioscience Corporate Events

Pure Bioscience Shareholders Back Governance, Expand Stock Authorization

Pure Bioscience, Inc. held its Annual Meeting of Stockholders on February 17, 2026, with approximately 66% of outstanding shares represented, and shareholders elected all seven director nominees with overwhelming majorities to serve until the next annual meeting. Investors also approved, on an advisory basis, the executive compensation program and ratified Weinberg & Company, P.A. as the independent auditor for the fiscal year ending July 31, 2026, signaling broad support for current governance and leadership.

In a key capital-structure move, shareholders voted to amend the company’s Certificate of Incorporation to increase authorized common stock from 200 million to 250 million shares, a step that provides added flexibility for future financing, equity compensation, or strategic transactions. No additional items were brought to a vote, underscoring that the meeting primarily reinforced existing governance arrangements while expanding the company’s capacity to issue new equity as needed.

The most recent analyst rating on (PURE) stock is a Hold with a $0.06 price target. To see the full list of analyst forecasts on Pure Bioscience stock, see the PURE Stock Forecast page.